The antitumor activity of exogenous and endogenous canstatin on colorectal cancer cells

Colorectal cancer is the third most common malignancy and the third-leading cause of cancer-related deaths worldwide. In the last several years, recombinant DNA technology has made cancer gene therapy feasible in the clinic. In our studies, we used both exogenous and endogenous canstatin, a type IV collagen genetically distinct product. We detected the effects of canstatin on colorectal cancer cells HCT-15 and HCT-116. DAPI staining, FCM and migration analyse were used to detect the apoptotic cells, cell cycle and mobility. As shown in the results, the apoptotic cell numbers (p0.05) and G1 arrest cell numbers (p0.05) were higher than in the non- treatment case. The mobility of the cells was also decreased obviously (p0.05). Simultaneously, combination effects of exogenous and endogenous canstatin were identified.